# Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)

> **NCT03893448** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1720 (actual)

## Conditions studied

- Pneumococcal Infections
- Pneumococcal Vaccines

## Interventions

- **BIOLOGICAL:** V114
- **BIOLOGICAL:** Prevnar 13™
- **BIOLOGICAL:** RotaTeq™
- **BIOLOGICAL:** Pentacel™
- **BIOLOGICAL:** RECOMBIVAX HB™
- **BIOLOGICAL:** VAQTA™
- **BIOLOGICAL:** MMR II™
- **BIOLOGICAL:** VARIVAX™
- **BIOLOGICAL:** HIBERIX™

## Key facts

- **NCT ID:** NCT03893448
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-19
- **Primary completion:** 2021-05-24
- **Final completion:** 2021-05-24
- **Target enrollment:** 1720 (ACTUAL)
- **Last updated:** 2023-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03893448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03893448, "Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT03893448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*